Amgen's new cancer drug treatment to cost US$178,000
San Francisco
AMGEN Inc's leukaemia drug Blincyto will cost US$178,000 for a standard course of treatment, continuing a trend of high prices for immunotherapy, the newest wave of cancer treatments.
The price includes two US$89,000 cycles of therapy, the median duration of treatment for patients who responded in clinical studies, said Danielle Bertrand, a spokeswoman for Amgen, the second-biggest US biotechnology company. Each cycle consists of four weeks of treatment.
Blincyto was approved by US regulators on Dec 3 for patients with an uncommon form of acute lymphoblastic leukaemia, a rapidly growing type of cancer in which the bone marrow makes too many B-cell lymphoblast…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
France's Casino supermarket chain to axe up to 3,200 jobs
Prada outshines rivals with 16% revenue lift boosted by Miu Miu
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Hilton lifts 2024 profit forecast on international travel demand
China knockoff raid jolts a global throng of fake-fashion influencers
Roche cuts pipeline after research setbacks and sales drop